Prolia (denosumab) may not reduce the risk of recurrence

The authors of these articles reviewed the studies that linked Prolia (denosumab) with reducing recurrence risk and do not accept the link:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30146-9/fulltext
https://www.ascopost.com/issues/june-25-2019/denosumab-prevents-neither-breast-cancer-relapse-nor-death/
https://www.medpagetoday.com/hematologyoncology/breastcancer/83757
https://www.cancernetwork.com/asco-breast-cancer/adjuvant-denosumab-fails-reduce-recurrences-deaths-early-breast-cancer
It is best to confirm the benefits and risks of the drug with your specialist.
I am posting these links as a reference and cannot engage in discussion about them.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30146-9/fulltext
https://www.ascopost.com/issues/june-25-2019/denosumab-prevents-neither-breast-cancer-relapse-nor-death/
https://www.medpagetoday.com/hematologyoncology/breastcancer/83757
https://www.cancernetwork.com/asco-breast-cancer/adjuvant-denosumab-fails-reduce-recurrences-deaths-early-breast-cancer
It is best to confirm the benefits and risks of the drug with your specialist.
I am posting these links as a reference and cannot engage in discussion about them.
0
Comments